The Expression and Action of Decay‐Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy | Zendy

JanHenrik Mikesch | Zendy; Kathrin Schier | Zendy; Antje Roetger | Zendy; Ronald Simon | Zendy; Horst Buerger | Zendy; Burkhard Brandt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Expression and Action of Decay‐Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy

Author(s) -

JanHenrik Mikesch,

Kathrin Schier,

Antje Roetger,

Ronald Simon,

Horst Buerger,

Burkhard Brandt

Publication year - 2006

Publication title -

analytical cellular pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.576

H-Index - 24

eISSN - 2210-7185

pISSN - 2210-7177

DOI - 10.1155/2006/814816

Subject(s) - cancer , action (physics) , expression (computer science) , cancer research , cancer therapy , decay accelerating factor , medicine , oncology , computer science , physics , immunology , antibody , complement system , quantum mechanics , programming language

Decay-accelerating factor (DAF, CD55) is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. Here DAF seems to exert different functions beyond its immunological role such as e.g. promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathways and specific seven-span transmembrane receptors (CD97) binding. Therefore, DAF has already become a target for therapy. In this paper we review the role of DAF in human malignancies as described in different basic, diagnostic and experimental therapeutic studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research